Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

When you or your bed partner has sleep apnea, a restful night’s sleep can be hard to come by. Treating this common condition ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

The end of compounded versions of weight-loss drugs is near, leaving patients scrambling for alternatives. Some “copycat” ...

In an increasingly competitive telehealth weight loss market, thoughtful and transparent branding is critical.

Weight loss medications like Wegovy and Zepbound can be effective but may pose risks for older adults, including muscle loss and bone density decline.

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development agreement. Zealand Pharma's ...